1477 Results

People

  1. Motzer
    Motzer
  2. Hudis
    Hudis
  3. Aghajanian
    Aghajanian
  4. O'Reilly
    O'Reilly
  5. Kris
    Kris
  6. Scher
    Scher
  7. Panageas
    Panageas
  8. Saltz
    Saltz
  9. Schwartz
    Schwartz
  10. Kelsen
    Kelsen

Groups

  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)
  7. Epidemiology and Biostatistics (194)
  8. Biostatistics Service (169)
  9. Gastrointestinal Oncology Service (160)
  10. Population Sciences Research Program (158)
  1. "fatigue"
Formats
  1. Journal Article (1402)
  2. Review (38)
  3. Research Letter (13)
  4. Editorial (10)
  5. Conference Paper (5)
  6. Guidelines (4)
  7. Correspondence (3)
  8. Book Section (2)
Groups
  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)

More Groups

People
  1. Robert Motzer (85)
  2. Clifford Hudis (49)
  3. Carol Aghajanian (46)
  4. Eileen O'Reilly (46)
  5. Howard Scher (44)
  6. Mark Kris (44)

More People

Years
  1. 2025 (60)
  2. 2024 (132)
  3. 2023 (89)
  4. 2022 (46)
  5. 2021 (33)
  6. 2020 (85)

More Years

Publications
  1. Journal of Clinical Oncology (108)
  2. Clinical Cancer Research (82)
  3. Cancer (63)
  4. Lancet Oncology (50)
  5. Gynecologic Oncology (41)
  6. Annals of Oncology (37)

More Publications

Publishers
  1. Elsevier Inc. (244)
  2. Springer (133)
  3. American Society of Clinical Oncology (114)
  4. Elsevier Science, Inc. (108)
  5. Oxford University Press (101)
  6. American Association for Cancer Research (89)

More Publishers

Results (1477)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A somatic BRCA2-mutated pancreatic adenocarcinoma with sustained exceptional response to modified FOLFIRINOX
    Journal Article

    Jamison, J. K.; May, M. S.; Raufi, A. G.; Luk, L.; Wong, W.; Mundi, P. S.; Manji, G. A.
    The Oncologist (2024)

    Fulltext@MSK | Save
  • A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: Phase 1 trial interim results
    Journal Article

    Rappaport, A. R.; Kyi, C.; Lane, M.; Hart, M. G.; Johnson, M. L.; Henick, B. S.; Liao, C. Y.; Mahipal, A.; Shergill, A.; Spira, A. I.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells
    Journal Article

    Yankelevich, M.; Thakur, A.; Modak, S.; Chu, R.; Taub, J.; Martin, A.; Schalk, D.; Schienshang, A.; Whitaker, S.; Rea, K.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
    Journal Article

    Epstein-Peterson, Z. D.; Drill, E.; Aypar, U.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamlin, P. A.; Ho, C.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Development of a customizable mouse backbone spectral flow cytometry panel to delineate immune cell populations in normal and tumor tissues
    Journal Article

    Longhini, A. L. F.; Fernández-Maestre, I.; Kennedy, M. C.; Wereski, M. G.; Mowla, S.; Xiao, W.; Lowe, S. W.; Levine, R. L.; Gardner, R.
    Frontiers in Immunology (2024)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended follow-up from the phase III randomised CheckMate 9ER trial
    Journal Article

    Powles, T.; Burotto, M.; Escudier, B.; Apolo, A. B.; Bourlon, M. T.; Shah, A. Y.; Suárez, C.; Porta, C.; Barrios, C. H.; Richardet, M.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save
  • A phase I study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer
    Journal Article

    Dorff, T.; Horvath, L. G.; Autio, K.; Bernard-Tessier, A.; Rettig, M. B.; Machiels, J. P.; Bilen, M. A.; Lolkema, M. P.; Adra, N.; Rottey, S.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Phase II DORA study of olaparib with or without durvalumab as a chemotherapy-free maintenance strategy in platinum-pretreated advanced triple-negative breast cancer
    Journal Article

    Tan, T. J.; Sammons, S.; Im, Y. H.; She, L.; Mundy, K.; Bigelow, R.; Traina, T. A.; Anders, C.; Yeong, J.; Renzulli, E.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Trastuzumab and pertuzumab in patients with non-breast/gastroesophageal HER2-amplified tumors: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol J
    Journal Article

    Connolly, R. M.; Wang, V.; Hyman, D. M.; Grivas, P.; Mitchell, E. P.; Wright, J. J.; Sharon, E.; Gray, R. J.; McShane, L. M.; Rubinstein, L. V.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Hepatic arterial infusion pump chemotherapy combined with systemic chemotherapy for borderline resectable and unresectable colorectal liver metastases: Phase II feasibility study
    Journal Article

    Krul, M. F.; Kok, N. F. M.; Osmani, H.; Buisman, F. E.; Koerkamp, B. G.; Grunhagen, D. J.; Verhoef, C.; Mostert, B.; Snaebjornsson, P.; Westerink, B.; more...
    British Journal of Surgery (2024)

    Fulltext@MSK | Save